• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

‘Nanolock’ could help diagnose and treat cancer with individualized therapies

July 5, 2017 By Sarah Faulkner

NanolockIn a study published in ACS Sensors, a team of researchers described how they develop a method to recognize a particular mutation in the genetic code of a cancerous cell.

If cancers are caught early enough in the cell mutation process, many of them can be stopped with chemotherapy and other forms of treatment. This new method could aid in early diagnosis and help researchers develop individualized treatments, according to the team.

Traditionally, cancer driver mutations are detected using real-time PCR, which selectively amplifies and copies mutant DNA sequences. But the technique is not accurate enough to reliably detect changes in the genetic code, the team reported. Researchers have also developed techniques to read a cell’s genetic sequence by passing it through a nanopore, but it is also not accurate enough by itself.

To remedy this problem, a team of researchers developed a “nanolock-nanopore” sensor. A nanolock stabilizes base pairs of DNA at a mutation site as it passes through a nanopore. Mutant DNA carrying a nanolock unzips in a unique way when it goes through the pore, according to team, leaving behind a highly accurate fingerprint.

The researchers were able to detect this marking for a mutation in the BRAF gene, which has been associated with a variety of cancers, including thyroid cancer.

The team reported that, combined with a miniature device, the detection method could allow for accurate, PCR-free detection of an array of disease-causing mutations.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diagnostics, Featured, Oncology, Pharmaceuticals, Research & Development

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS